JW Lifescience Corporation (KRX:234080)
South Korea
· Delayed Price · Currency is KRW 12,490
-440 (-3.40%)
Mar 9, 2026, 3:30 PM KST
JW Lifescience Revenue
JW Lifescience had revenue of 62.61B KRW in the quarter ending September 30, 2025, with 8.04% growth. This brings the company's revenue in the last twelve months to 248.30B, up 12.19% year-over-year. In the year 2024, JW Lifescience had annual revenue of 222.48B with 7.55% growth.
Revenue (ttm)
248.30B
Revenue Growth
+12.19%
P/S Ratio
0.78
Revenue / Employee
836.02M
Employees
297
Market Cap
193.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 222.48B | 15.62B | 7.55% |
| Dec 31, 2023 | 206.86B | 17.93B | 9.49% |
| Dec 31, 2022 | 188.93B | 19.11B | 11.26% |
| Dec 31, 2021 | 169.82B | -13.70B | -7.47% |
| Dec 31, 2020 | 183.52B | 13.30B | 7.81% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AptaBio Therapeutics | 3.44B |
| REYON Pharmaceutical | 149.34B |
| Jeil Pharmaceutical Co.,Ltd | 621.98B |
| HLB Pharmaceutical | 36.10B |
| Samjin Pharmaceuticals | 274.03B |
| Samil Pharmaceutical Co.,Ltd | 215.04B |
| SAMSUNG PHARM. Co., LTD. | 44.29B |
| Daewon Pharmaceutical | 590.70B |